Federal contract award
75N93023C00055
TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $11.3M |
| Current contract value | $11.3M |
| Potential contract value / ceiling | $12.4M |
| Start date | Sep 25, 2023 |
| Current end date | Dec 31, 2026 |
| Potential end date | Dec 31, 2026 |
| Latest award activity | Mar 24, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 8 of 8 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Mar 24, 2026 | P00007 | $2.6M | TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1. |
| Jul 23, 2024 | P00006 | $0 | TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1. |
| Jul 1, 2024 | P00005 | $6.2M | TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1. |
| Jun 18, 2024 | P00004 | $0 | TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1. |
| Apr 16, 2024 | P00003 | $0 | TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1. |
| Feb 14, 2024 | P00002 | $754.6K | TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1. |
| Dec 12, 2023 | P00001 | $0 | TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1. |
| Sep 21, 2023 | 0 | $1.8M | TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1. |
Estimated positioning window
Nov 1, 2026 – Jan 30, 2027
80/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 80/100. Available recorded signals: 75 points.
- Contract end 2026-12-31 (60 days from calculation)
- +35 points
- 155 historical awards in this buyer and category group
- +15 points
- 8 recorded award transactions
- +10 points
- Latest award action: 2026-03-24
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Julie Rodriguez | Contact | julie.rodriguez@nih.gov 3017617735 | Source | Apr 8, 2022 |
| Brian Madgey | Contact | brian.madgey@nih.gov 2406273712 | Source | Apr 8, 2022 |
| Julie Rodriguez | Contact | julie.rodriguez@nih.gov 3017617735 | Source | Mar 16, 2022 |
| Brian Madgey | Contact | brian.madgey@nih.gov 2406273712 | Source | Mar 16, 2022 |
| Julie Rodriguez | Contact | julie.rodriguez@nih.gov 3017617735 | Source | Feb 17, 2022 |
| Brian Madgey | Contact | brian.madgey@nih.gov 2406273712 | Source | Feb 17, 2022 |
| Julie Rodriguez | Contact | julie.rodriguez@nih.gov 3017617735 | Source | Feb 14, 2022 |
| Brian Madgey | Contact | brian.madgey@nih.gov 2406273712 | Source | Feb 14, 2022 |
| Julie Rodriguez | Contact | julie.rodriguez@nih.gov 3017617735 | Source | Jan 18, 2022 |
| Brian Madgey | Contact | brian.madgey@nih.gov 2406273712 | Source | Jan 18, 2022 |
| Julie Rodriguez | Contact | julie.rodriguez@nih.gov 3017617735 | Source | Jan 4, 2022 |
| Brian Madgey | Contact | brian.madgey@nih.gov 2406273712 | Source | Jan 4, 2022 |
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.